BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rasonque (Daraxonrasib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rasonque (Daraxonrasib)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06040541-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Rasonque (Daraxonrasib): Phase 1 readout est. (NCT06040541)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1\, Non-Small Cell Lung Cancer.
 \nStudy: Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tum
 ors\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/daraxonrasib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06040541
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05379985-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT05379985)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of RMC-6236 in Patients With Advanced Solid Tumors Harbor
 ing Specific Mutations in RAS\nEstimated primary completion: 31 May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05379985
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06162221-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06162221)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutat
 ed NSCLC\nEstimated primary completion: June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/daraxonrasib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06162221
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922591-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06922591)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study to Evaluate the Safety\, Tolerability & Efficacy of TNG46
 2 in Combination in PDAC & NSCLC Patients\nEstimated primary completion: J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 922591
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881784-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT06881784)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSC
 LC (RASolve 301)\nEstimated primary completion: 1 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06881784
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07349537-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Rasonque (Daraxonrasib): Phase 1 readout est. (NCT07349537)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1\, Non-Small Cell Lung Cancer.
 \nStudy: Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Soli
 d Tumors\nEstimated primary completion: April 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/daraxonrasib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07349537
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07491445-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT07491445)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Study of Daraxonrasib and Daraxonrasib + GnP as First-line 
 Treatment in Patients With Metastatic Pancreatic Adenocarcinoma\nEstimated
  primary completion: April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/daraxonrasib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07491445
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492680-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Rasonque (Daraxonrasib): Phase 2 readout est. (NCT07492680)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 2.\nStudy: A Study of Navlimeto
 stat (BMS-986504) Monotherapy and in Combination With Other Agents in Part
 icipants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP
  Deletion (MountainTAP-5)\nEstimated primary completion: 15 August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07492680
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445062-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06445062)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Pancreatic Ductal Adenoca
 rcinoma.\nStudy: Study of RAS(ON) Inhibitors in Patients With Gastrointest
 inal Solid Tumors\nEstimated primary completion: 30 September 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06445062
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128551-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06128551)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of Elironrasib and Daraxonrasib as Monotherapies and Comb
 ination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumor
 s\nEstimated primary completion: December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/daraxonrasib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06128551
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07898813-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20290217
DTEND;VALUE=DATE:20290218
SUMMARY:Rasonque (Daraxonrasib): Phase 1 readout est. (NCT07898813)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Daraxonrasib in Resectable PDAC\nEstimated primary completi
 on: 17 February 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /daraxonrasib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07898813
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07805954-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT07805954)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236
 ) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metasta
 tic KRAS G12D-Mutated Pancreatic Adenocarcinoma\nEstimated primary complet
 ion: March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dara
 xonrasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07805954
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397338-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT07397338)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of RAS(ON) Inhibitors in Combination With Ivonescimab in 
 Patients With Solid Tumors\nEstimated primary completion: May 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07397338
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252232-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20290510
DTEND;VALUE=DATE:20290511
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT07252232)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Pancreatic Ductal Adenocarc
 inoma.\nStudy: Study of Daraxonrasib (RMC-6236) in Patients With Resected 
 Pancreatic Ductal Adenocarcinoma (PDAC)\nEstimated primary completion: 10 
 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 252232
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07756281-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Rasonque (Daraxonrasib): Phase 1 readout est. (NCT07756281)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1.\nStudy: First in Human Study
  of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cance
 r\nEstimated primary completion: 1 June 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/daraxonrasib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07756281
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908550-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rasonque (Daraxonrasib): Phase 2 readout est. (NCT07908550)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 2.\nStudy: Daraxonrasib in Asia
 n RAS-mutant Biliary Tract Cancer\nEstimated primary completion: December 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT079085
 50
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793253-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Rasonque (Daraxonrasib): Phase 2 readout est. (NCT07793253)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 2.\nStudy: Phase 2 Study of Dar
 axonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer\nEstimated primary
  completion: November 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/daraxonrasib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07793253
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819838-2216@assetmemo.bio
DTSTAMP:20261121T005631Z
DTSTART;VALUE=DATE:20320409
DTEND;VALUE=DATE:20320410
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT07819838)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2.\nStudy: Testing the Additi
 on of an Anti-Cancer Drug\, Daraxonrasib\, for Relapsed or Refractory Soli
 d Tumors With RAS Mutations\nEstimated primary completion: 9 April 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07819838
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
